Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELVN Enliven Therapeutics	$16.86 -5.4%	$18.84	$13.30 ▼ $30.03	$827.25M	1.07	264,191 shs	473,950 shs
GLUE Monte Rosa Therapeutics	$3.98 +2.8%	$4.83	$3.21 ▼ $12.40	$244.81M	1.52	1.06 million shs	421,565 shs
RCUS Arcus Biosciences	$8.56 -0.1%	$8.28	$6.50 ▼ $18.98	$906.38M	0.88	839,542 shs	920,596 shs
SYRE Spyre Therapeutics	$15.18 +4.4%	$14.92	$10.91 ▼ $40.26	$914.99M	2.78	612,468 shs	340,714 shs

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELVN Enliven Therapeutics	-10.41%	-4.35%	+4.52%	-17.80%	-25.75%
GLUE Monte Rosa Therapeutics	+4.59%	-8.08%	-12.64%	-42.92%	-26.00%
RCUS Arcus Biosciences	+0.12%	+0.29%	+7.07%	-34.33%	-51.17%
SYRE Spyre Therapeutics	-1.76%	+12.98%	+14.40%	-36.56%	-61.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELVN Enliven Therapeutics	2.5618 of 5 stars	3.6	2.0	1.9	4.2	0.0
GLUE Monte Rosa Therapeutics	2.2226 of 5 stars	3.4	0.0	3.0	3.3	0.6
RCUS Arcus Biosciences	2.952 of 5 stars	4.5	1.0	1.8	4.2	0.0
SYRE Spyre Therapeutics	3.1147 of 5 stars	4.6	0.0	4.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELVN Enliven Therapeutics	3.20	Buy	$37.25	120.94% Upside
GLUE Monte Rosa Therapeutics	2.75	Moderate Buy	$15.50	289.45% Upside
RCUS Arcus Biosciences	2.91	Moderate Buy	$25.67	199.84% Upside
SYRE Spyre Therapeutics	3.25	Buy	$53.40	251.78% Upside

Current Analyst Ratings Breakdown

Latest GLUE, RCUS, SYRE, and ELVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
5/5/2025	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
4/23/2025	RCUS Arcus Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $14.00
4/8/2025	SYRE Spyre Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/8/2025	SYRE Spyre Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
3/21/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $39.00

(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$5.97 per share	N/A
GLUE Monte Rosa Therapeutics	$159.49M	1.53	N/A	N/A	$3.58 per share	1.11
RCUS Arcus Biosciences	$141M	6.43	N/A	N/A	$6.17 per share	1.39
SYRE Spyre Therapeutics	$890K	1,028.08	N/A	N/A	($0.22) per share	-69.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELVN Enliven Therapeutics	-$71.58M	-$1.89	N/A	N/A	N/A	N/A	-29.46%	-27.33%	N/A
GLUE Monte Rosa Therapeutics	-$135.35M	$0.08	N/A	N/A	N/A	N/A	-62.68%	-38.83%	N/A
RCUS Arcus Biosciences	-$307M	-$4.19	N/A	N/A	N/A	-102.66%	-45.59%	-22.38%	N/A
SYRE Spyre Therapeutics	-$338.79M	-$3.77	N/A	N/A	N/A	N/A	-210.01%	-44.40%	N/A

Latest GLUE, RCUS, SYRE, and ELVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/8/2025	Q1 2025	GLUE Monte Rosa Therapeutics	-$0.24	$0.57	+$0.81	$0.57	$13.57 million	$84.93 million
5/8/2025	Q1 2025	SYRE Spyre Therapeutics	-$0.76	-$0.74	+$0.02	-$0.74	N/A	N/A
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million
3/20/2025	Q4 2024	GLUE Monte Rosa Therapeutics	-$0.37	$0.23	+$0.60	$0.23	$43.73 million	$14.00 million
3/13/2025	Q4 2024	ELVN Enliven Therapeutics	-$0.53	-$0.46	+$0.07	-$0.46	N/A	$0.03 million
2/27/2025	Q4 2024	SYRE Spyre Therapeutics	-$0.89	-$0.81	+$0.08	-$0.81	$2.10 million	N/A
2/25/2025	Q4 2024	RCUS Arcus Biosciences	-$1.17	-$1.03	+$0.14	-$1.03	$29.38 million	$36.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELVN Enliven Therapeutics	N/A	17.44	17.44
GLUE Monte Rosa Therapeutics	N/A	6.03	6.03
RCUS Arcus Biosciences	0.08	5.24	5.24
SYRE Spyre Therapeutics	N/A	7.32	7.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELVN Enliven Therapeutics	95.08%
GLUE Monte Rosa Therapeutics	79.96%
RCUS Arcus Biosciences	92.89%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
ELVN Enliven Therapeutics	29.20%
GLUE Monte Rosa Therapeutics	6.90%
RCUS Arcus Biosciences	12.30%
SYRE Spyre Therapeutics	6.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELVN Enliven Therapeutics	50	49.07 million	34.59 million	Optionable
GLUE Monte Rosa Therapeutics	90	61.51 million	57.44 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	80.26 million	Optionable
SYRE Spyre Therapeutics	100	60.28 million	48.24 million	Optionable

GLUE, RCUS, SYRE, and ELVN Headlines

Recent News About These Companies

Paradigm Biocapital Advisors LP Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

May 16 at 8:35 AM | marketbeat.com

How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%

May 13 at 11:00 AM | zacks.com

Jefferies Financial Group Inc. Has $28.33 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

May 13 at 7:54 AM | marketbeat.com

First Trust Advisors LP Invests $548,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

May 12, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Up 12.6% After Strong Earnings

May 11, 2025 | americanbankingnews.com

Analysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ)

May 10, 2025 | theglobeandmail.com

Deerfield Management Company L.P. Series C Purchases Shares of 450,000 Spyre Therapeutics, Inc. (NASDAQ:SYRE)

May 10, 2025 | marketbeat.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Holdings Raised by Driehaus Capital Management LLC

May 10, 2025 | marketbeat.com

Spyre Therapeutics, Inc.: Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 9, 2025 | finanznachrichten.de

Deep Track Capital LP Lowers Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

May 9, 2025 | marketbeat.com

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025 | prnewswire.com

Braidwell LP Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

May 8, 2025 | marketbeat.com

Blackstone Inc. Acquires 156,206 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

May 8, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Trading Down 5.8% - Here's Why

May 7, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Receives "Outperform" Rating from Wedbush

May 7, 2025 | marketbeat.com

Why Spyre Therapeutics, Inc.’s (SYRE) Stock Is Down 5.11%

May 7, 2025 | aaii.com

Spyre Therapeutics' (SYRE) "Outperform" Rating Reiterated at Wedbush

May 7, 2025 | americanbankingnews.com

Invesco Ltd. Sells 118,195 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

May 6, 2025 | marketbeat.com

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

May 5, 2025 | prnewswire.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of "Buy" from Analysts

May 5, 2025 | marketbeat.com

Price T Rowe Associates Inc. MD Acquires 77,323 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

May 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE, RCUS, SYRE, and ELVN Company Descriptions

Enliven Therapeutics NASDAQ:ELVN

$16.86 -0.96 (-5.39%)

Closing price 04:00 PM Eastern

Extended Trading

$16.89 +0.03 (+0.18%)

As of 04:05 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Monte Rosa Therapeutics NASDAQ:GLUE

$3.98 +0.11 (+2.84%)

Closing price 04:00 PM Eastern

Extended Trading

$4.06 +0.07 (+1.88%)

As of 04:27 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Arcus Biosciences NYSE:RCUS

$8.56 -0.01 (-0.12%)

Closing price 03:59 PM Eastern

Extended Trading

$8.56 -0.01 (-0.06%)

As of 05:57 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Spyre Therapeutics NASDAQ:SYRE

$15.18 +0.64 (+4.40%)

Closing price 04:00 PM Eastern

Extended Trading

$15.20 +0.02 (+0.10%)

As of 05:24 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time